Eiger BioPharmaceuticals Investor Relations Material
Latest events
Status Update
Eiger BioPharmaceuticals
Q4 2023
8 Apr, 2024
Q3 2023
9 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Eiger BioPharmaceuticals Inc
Access all reports
Eiger BioPharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases. The company’s therapeutic areas include infectious diseases, metabolic disorders, and genetic conditions. Eiger’s pipeline targets diseases with high unmet medical needs, and it works to bring new treatment options to patients who have limited alternatives. Its approach involves repurposing existing drugs and developing novel compounds to advance its treatment options through clinical trials and regulatory approvals. The company is headquartered in Palo Alto, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
EIGR
Country
🇺🇸 United States